Phase I, open-label study to evaluate the pharmacokinetics, tolerability and short-term
safety of ciprofloxacin in neonates with suspected (or proven) Gram Negative infection.
Objectives: To evaluate the multiple-dose pharmacokinetics of ciprofloxacin in neonates and
young infants (24 - 52 weeks postmenstrual age) with suspected or proven Gram Negative
To evaluate the tolerability and describe short-term safety of ciprofloxacin in neonates and
young infants with suspected (or proven) Gram Negative infection.
To describe the clinical outcomes of neonates treated with ciprofloxacin